← Back to All Filings

Teva Pharmaceutical Announces Multi-Tranche USD and EUR Senior Notes Offering

Medium SignificanceSeptember 8, 2026 at 11:07:14 AM UTC

TEVA PHARMACEUTICAL INDUSTRIES LTD

$TEVA424B5CIK: 0000818686

Subscribe to track TEVA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

📋 Teva Pharmaceutical Industries Ltd (TEVA) filed Form 424B5 for a preliminary multi-tranche senior notes offering in USD and EUR guaranteed by the parent company. Net proceeds are intended to fund conditional redemptions of near-term outstanding notes and for general corporate purposes.

Comprehensive Analysis

Offering Overview

Teva Pharmaceutical Industries Ltd. filed a preliminary prospectus supplement (Form 424B5) on September 8, 2026, relating to a multi-tranche senior debt offering through three of its Dutch financing subsidiaries:

  • Teva Pharmaceutical Finance Netherlands II B.V.: Senior Notes due 2033 (EUR) and Senior Notes due 2036 (EUR)
  • Teva Pharmaceutical Finance Netherlands III B.V.: Senior Notes due 2034 (USD) and Senior Notes due 2037 (USD)
  • Teva Pharmaceutical Finance Netherlands IV B.V.: Senior Notes due 2032 (USD)

All notes will be fully and unconditionally guaranteed on a senior unsecured basis by Teva Pharmaceutical Industries Limited.


Use of Proceeds & Debt Refinancing

The net proceeds from the offering, along with cash on hand, are slated for:

  1. Conditional Redemptions: Refinancing existing indebtedness, including:
    • Full redemption of outstanding 6.750% Senior Notes due 2028 (USD)
    • Full redemption of outstanding 7.875% Sustainability-Linked Senior Notes due 2029 (USD)
    • Full redemption of outstanding 7.375% Sustainability-Linked Senior Notes due 2029 (EUR)
    • Up to $450 million aggregate principal amount of 4.750% Sustainability-Linked Senior Notes due 2027 (USD)
    • Up to €1.25 billion aggregate principal amount of 4.375% Sustainability-Linked Senior Notes due 2030 (EUR)
  2. Payment of related fees and transaction expenses.
  3. General corporate purposes and potential further debt reduction.

Key Underwriters

  • Active Joint Book-Running Managers: BNP PARIBAS, Citigroup, Goldman Sachs Bank Europe SE, J.P. Morgan
  • Passive Joint Book-Running Managers: BofA Securities, HSBC, Mizuho
Topics:#TEVA#DebtOffering#Bonds#Refinancing#Pharma

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.

The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.

Always do your own due diligence and consult a licensed professional.